EGFR and non-small cell lung carcinoma: A total of 85 advanced NSCLC patients, enrolled at Zhejiang Cancer Hospital from July 15, 2016 to March 22, 2022, and harboring EGFR mutations received ICIs for progression after prior EGFR-TKI treatments.